FI118590B - 1-hydroksi -2- (imidatsol -1-yyli) etaani -1,1 -difosfonihapon käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen - Google Patents

1-hydroksi -2- (imidatsol -1-yyli) etaani -1,1 -difosfonihapon käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen Download PDF

Info

Publication number
FI118590B
FI118590B FI964332A FI964332A FI118590B FI 118590 B FI118590 B FI 118590B FI 964332 A FI964332 A FI 964332A FI 964332 A FI964332 A FI 964332A FI 118590 B FI118590 B FI 118590B
Authority
FI
Finland
Prior art keywords
prosthesis
migration
imidazol
ethane
hydroxy
Prior art date
Application number
FI964332A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI964332A0 (fi
FI964332A (fi
Inventor
Jonathan Green
Allen E Goodship
John Kenwright
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of FI964332A0 publication Critical patent/FI964332A0/fi
Publication of FI964332A publication Critical patent/FI964332A/fi
Application granted granted Critical
Publication of FI118590B publication Critical patent/FI118590B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI964332A 1994-05-04 1996-10-28 1-hydroksi -2- (imidatsol -1-yyli) etaani -1,1 -difosfonihapon käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen FI118590B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9408775A GB9408775D0 (en) 1994-05-04 1994-05-04 Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
GB9408775 1994-05-04
IB9500288 1995-04-24
PCT/IB1995/000288 WO1995030421A1 (en) 1994-05-04 1995-04-24 Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration

Publications (3)

Publication Number Publication Date
FI964332A0 FI964332A0 (fi) 1996-10-28
FI964332A FI964332A (fi) 1996-10-28
FI118590B true FI118590B (fi) 2008-01-15

Family

ID=10754497

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964332A FI118590B (fi) 1994-05-04 1996-10-28 1-hydroksi -2- (imidatsol -1-yyli) etaani -1,1 -difosfonihapon käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen

Country Status (18)

Country Link
US (1) US5965547A (de)
EP (1) EP0758241B1 (de)
JP (1) JPH09512816A (de)
AT (1) ATE218350T1 (de)
AU (1) AU693541B2 (de)
DE (1) DE69526937T2 (de)
DK (1) DK0758241T3 (de)
ES (1) ES2177642T3 (de)
FI (1) FI118590B (de)
GB (1) GB9408775D0 (de)
HU (1) HUT74984A (de)
IL (1) IL113566A (de)
NO (1) NO310057B1 (de)
NZ (1) NZ283430A (de)
PT (1) PT758241E (de)
TW (1) TW458779B (de)
WO (1) WO1995030421A1 (de)
ZA (1) ZA953537B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
GB2336311A (en) * 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
US6137012A (en) 1998-10-13 2000-10-24 E. I. Du Pont De Nemours And Company Phosphole and diphosphole ligands for catalysis
TR200101546T2 (tr) * 1998-12-04 2001-11-21 Roche Diagnostics Gmbh İç-protezlerde kemik entegrasyonunu iyileştirmek üzere ibandronat kullanılması.
AU776555B2 (en) * 1999-02-09 2004-09-16 Sloan-Kettering Institute For Cancer Research Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts
US6692758B1 (en) * 1999-08-02 2004-02-17 Toray Industries, Inc. Insertion stabilizers for implants
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
EP1591122B1 (de) 2000-06-20 2012-09-26 Novartis AG Methode zur Verabreichung von Biphosphonaten
US8052987B2 (en) * 2000-06-20 2011-11-08 Novartis Pharmaceuticals Corporation Method of administering bisphosphonates
AU2001287260A1 (en) * 2000-07-12 2002-01-21 Ecole Polytechnique Federale De Lausanne (Epfl) Active biocoating for bone implant
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
PT1506041E (pt) * 2002-05-10 2007-12-28 Hoffmann La Roche Ácido ibandrónico para o tratamento e a prevenção da osteoporose
AU2003270196A1 (en) * 2002-09-16 2004-04-30 Kenneth W. Lyles Method for preventing or reducing secondary fractures after hip fracture
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
EP2088996A1 (de) * 2006-11-17 2009-08-19 Besins Healthcare Flüssige pharmazeutische zusammensetzungen mit einer bisphosphonat-verbindung
EP1958649A1 (de) * 2007-02-14 2008-08-20 Graftys Injizierbarer Kalzium-Phospat-Zement zur Freisetzung eines Knochenschwund-Inhibitors
EP2136814A4 (de) * 2007-03-21 2012-05-30 Univ Duke Medikationskits und formulierungen zur verhütung, behandlung oder reduzierung von sekundären frakturen nach einer vorhergehenden fraktur
WO2008152518A2 (en) * 2007-05-16 2008-12-18 Actavis Group Ptc Ehf Process for the preparation of risedronic acid or risedronate sodium
HUE025737T2 (en) 2009-09-01 2016-05-30 Univ Duke Bisphosphonate compositions and methods for treating heart failure
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
JP6261512B2 (ja) 2011-11-16 2018-01-17 デューク ユニバーシティ 心機能障害を治療及び／又は低減するためのビスホスホネート組成物並びに方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3776880D1 (de) * 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
JPH05163150A (ja) * 1991-05-13 1993-06-29 E R Squibb & Sons Inc アテローム性動脈硬化症の抑制・治療剤
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices

Also Published As

Publication number Publication date
EP0758241B1 (de) 2002-06-05
ATE218350T1 (de) 2002-06-15
AU693541B2 (en) 1998-07-02
NO310057B1 (no) 2001-05-14
FI964332A0 (fi) 1996-10-28
EP0758241A1 (de) 1997-02-19
DE69526937D1 (de) 2002-07-11
GB9408775D0 (en) 1994-06-22
AU2146695A (en) 1995-11-29
IL113566A0 (en) 1995-08-31
DK0758241T3 (da) 2002-09-23
ZA953537B (en) 1995-11-06
NO964486D0 (no) 1996-10-22
NO964486L (no) 1996-10-22
HUT74984A (en) 1997-03-28
IL113566A (en) 2002-05-23
HU9603042D0 (en) 1997-01-28
NZ283430A (en) 2000-06-23
TW458779B (en) 2001-10-11
ES2177642T3 (es) 2002-12-16
WO1995030421A1 (en) 1995-11-16
JPH09512816A (ja) 1997-12-22
DE69526937T2 (de) 2003-01-02
US5965547A (en) 1999-10-12
FI964332A (fi) 1996-10-28
PT758241E (pt) 2002-10-31

Similar Documents

Publication Publication Date Title
FI118590B (fi) 1-hydroksi -2- (imidatsol -1-yyli) etaani -1,1 -difosfonihapon käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
CN1078073C (zh) 二膦酸盐在矫形假体移植后在抑制骨再吸收中的应用
EP1296689B3 (de) Methode zur verabreichung von biphosphonaten
SK287501B6 (sk) Použitie kyseliny zoledrónovej na prípravu liečiva na liečenie bolesti
IL110350A (en) Medical combination of the parathyroid hormone and relaxoxin to freeze bone mass
WO1996039107A1 (en) Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
CN102844033A (zh) 提高植入物骨结合的方法和组合物
EP0600834A1 (de) Verwendung von Methanbiphosphonsäurederivaten zur Herstellung eines Arzneimittels zur Behandlung von Knochenbrüchen
AU670337B2 (en) Use of certain methanebisphosphonic acid derivatives in fracture healing
Reginster Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review
Richardson et al. First place—resident basic science award 1993: Risedronate activity in the fetal and neonatal mouse
EP1591122B1 (de) Methode zur Verabreichung von Biphosphonaten
CA2183764C (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
RU2325170C1 (ru) Биокомпозиционный материал для остеопластики
MXPA96005327A (en) Use of certain derivatives of acidometanisphisphonic to prevent the loosening of protesis and the emigration of proteins
Shanbhag et al. Localized Osteolysis after Joint Replacement Surgery
AU2005203308A1 (en) Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

FG Patent granted

Ref document number: 118590

Country of ref document: FI